An Open-Label, Comparative, Parallel Clinical Trial of the Safety, Pharmacokinetics and Immunogenicity of the Ustekinumab Biosimilar GNR-068 and the Originally Developed Ustekinumab as a Reference Drug After a Single Subcutaneous Administration in Healthy Male Volunteers
Antibodies · 12.08.2026 · 15 (4) · 77
DOI: 10.3390/antib15040077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibodies, online erschienen am 12.08.2026. Verfasst von Ivan Lyagoskin und 7 weiteren Autor:innen. Beteiligte Einrichtung: JSC "GENERIUM", 14, Vladimirskaya Street, Volginskiy 601125, Vladimir Region, Russia. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
GNR-068 is a proposed biosimilar to the ustekinumab reference product (RP), which works through the antagonism of interleukin 12 and interleukin 23. Ustekinumab RP is used for the treatment of chronic inflammatory conditions, including certain forms of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Objectives
The purpose of the study is to study the safety, pharmacokinetics, and immunogenicity of the ustekinumab biosimilar GNR-068 and the reference drug Stelara® after a single subcutaneous administration in healthy male volunteers.
Methods
This was an open-label, randomized, comparative, parallel-group clinical trial of the safety, pharmacokinetics (PK), and immunogenicity of GNR-068 (JSC GENERIUM) and Stelara® (Manufacturer: Silag AG, Switzerland; RU Holder: JOHNSON & JOHNSON) after a single subcutaneous administration of 45 mg in healthy volunteers. During the trial, 146 volunteers were screened, and 122 were randomized.
Results
The results showed that PK similarity was established based on 90% confidence intervals (CIs) for the ratios of geometric means of the primary endpoints of area under the concentration-time curve from time 0 extrapolated to infinity (AUC0–∞) and maximum observed serum concentration (Cmax) being contained within the pre-specified margin of 80.00–125.00%. The incidence of total ADA was lower in the GNR-068 group compared with the reference product group. Adverse events were similar between treatment groups and consistent with the safety profile of the ustekinumab RP.
Conclusions
These results indicate that GNR-068 and the ustekinumab RP share similar PK and safety profiles.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- JSC "GENERIUM", 14, Vladimirskaya Street, Volginskiy 601125, Vladimir Region, Russia.
ORCID-Profile: Ivan Lyagoskin, Rakhim Shukurov, Ravil Khamitov
Zitieren
APA
Lyagoskin, I., Agafonova, A., Shevchenko, I., Akhtyamova-Givirovskaya, N., Markova, O., Pantyushenko, M., Shukurov, R., & Khamitov, R. (2026). An Open-Label, Comparative, Parallel Clinical Trial of the Safety, Pharmacokinetics and Immunogenicity of the Ustekinumab Biosimilar GNR-068 and the Originally Developed Ustekinumab as a Reference Drug After a Single Subcutaneous Administration in Healthy Male Volunteers. Antibodies, 15(4), 77. https://doi.org/10.3390/antib15040077
Vancouver
Lyagoskin I, Agafonova A, Shevchenko I, Akhtyamova-Givirovskaya N, Markova O, Pantyushenko M, et al. An Open-Label, Comparative, Parallel Clinical Trial of the Safety, Pharmacokinetics and Immunogenicity of the Ustekinumab Biosimilar GNR-068 and the Originally Developed Ustekinumab as a Reference Drug After a Single Subcutaneous Administration in Healthy Male Volunteers. Antibodies. 2026;15(4):77. doi:10.3390/antib15040077
BibTeX
@article{Lyagoskin2026,
author = {Lyagoskin, Ivan and Agafonova, Alena and Shevchenko, Ivan and Akhtyamova-Givirovskaya, Nina and Markova, Oksana and Pantyushenko, Marina and Shukurov, Rakhim and Khamitov, Ravil},
title = {An Open-Label, Comparative, Parallel Clinical Trial of the Safety, Pharmacokinetics and Immunogenicity of the Ustekinumab Biosimilar GNR-068 and the Originally Developed Ustekinumab as a Reference Drug After a Single Subcutaneous Administration in Healthy Male Volunteers},
journal = {Antibodies},
year = {2026},
volume = {15},
number = {4},
pages = {77},
doi = {10.3390/antib15040077}
}
EUVIMED